Stock listing

NASDAQ:GPCR Structure Therapeutics, Inc. Stock

Follow Structure Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GPCR

$16.13 USD -1.23 (-7.1%)

Close on Nov 20, 2026

Past year -53.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$16.08 – $17.08 USDNov 20, 2026
Volume
786,126 sharesNov 20, 2026
Market cap
$1.15B USDAt the close on Nov 20, 2026 · price × 71.31M shares outstanding
52-week range
$16.08 – $94.90 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$36.08M USDMedian day 1.06M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GPCR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$16.13-1.23-7.1%$16.73$17.08$16.08786,126
$17.36-0.81-4.5%$18.16$18.57$17.341,100,378
$18.17-0.40-2.2%$18.53$18.69$17.81583,625
$18.57-1.43-7.1%$19.82$19.99$18.38761,993
$20.00+0.16+0.8%$19.89$20.50$19.091,345,855
$19.84-1.11-5.3%$20.50$21.00$19.621,037,288
$20.95-0.78-3.6%$21.79$21.99$20.781,001,659
$21.73+0.32+1.5%$21.41$22.72$21.021,443,668
$21.41+1.06+5.2%$20.57$22.13$20.571,235,540
$20.35+1.27+6.7%$19.44$21.31$18.701,615,812
$19.08-1.28-6.3%$20.47$20.56$18.761,011,097
$20.36+0.010.0%$20.69$21.48$19.94738,485
$20.35-0.12-0.6%$20.70$21.16$20.30612,850
$20.47-1.40-6.4%$22.05$22.05$20.42788,016
$21.87-0.07-0.3%$21.59$22.36$21.07695,900
$21.94+0.46+2.1%$21.51$22.16$21.39929,400
$21.48-0.07-0.3%$21.29$21.67$20.50987,400
$21.55+0.45+2.1%$21.15$22.08$20.90731,600
$21.10-0.09-0.4%$21.16$21.98$21.05685,900
$21.19-0.74-3.4%$21.79$21.97$21.13796,800
$21.93-0.08-0.4%$21.72$22.55$21.72701,300
$22.01-0.87-3.8%$23.00$23.32$21.77804,400
$22.88+0.87+4.0%$22.11$23.83$22.111,408,600
$22.01+0.93+4.4%$21.08$22.25$20.741,312,600
$21.08-1.11-5.0%$22.15$22.21$20.731,160,800
$22.19+0.31+1.4%$21.89$22.62$21.811,411,000
$21.88-0.43-1.9%$22.46$22.89$21.552,068,200
$22.31-1.60-6.7%$23.92$24.03$22.101,434,800
$23.91-1.63-6.4%$25.25$25.50$23.891,660,300
$25.54-0.13-0.5%$25.73$26.15$25.29592,800
$25.67-1.01-3.8%$26.57$26.80$25.09939,200
$26.68-0.79-2.9%$27.14$28.05$26.381,048,800
$27.47-0.12-0.4%$27.55$27.85$26.691,421,500
$27.59-0.08-0.3%$28.10$28.21$26.411,867,800
$27.67-1.31-4.5%$28.99$29.25$27.571,713,500
$28.98-2.29-7.3%$31.27$31.39$28.932,591,700
$31.27-1.42-4.3%$33.05$33.05$31.082,197,000
$32.69-2.375-6.8%$34.78$34.93$32.441,726,400
$35.07-0.865-2.4%$34.86$35.64$34.431,282,600
$35.93-0.09-0.2%$36.29$37.20$35.501,587,800
$36.02+0.07+0.2%$35.35$36.27$34.432,110,900
$35.95-0.96-2.6%$36.50$37.30$34.961,400,500
$36.91+0.10+0.3%$36.99$37.74$36.25611,200
$36.81+1.81+5.2%$35.34$36.99$35.001,021,500
$35.00-0.10-0.3%$35.04$35.63$34.421,546,900
$35.10-0.40-1.1%$36.05$36.45$35.051,178,200
$35.50-3.45-8.9%$39.19$39.19$35.421,648,900
$38.95+0.51+1.3%$38.36$39.03$37.751,466,100
$38.44-0.22-0.6%$38.92$39.24$37.821,498,300
$38.66-0.89-2.3%$39.82$40.27$38.101,276,100
$39.55-1.68-4.1%$40.51$40.90$39.29761,400
$41.23+0.85+2.1%$41.23$44.94$40.491,562,300
$40.38-6.96-14.7%$46.84$47.38$40.263,409,900
$47.340.000.0%$47.26$48.06$46.73281,700
$47.34-0.46-1.0%$48.21$48.25$46.37621,400
$47.80+0.67+1.4%$47.76$48.64$46.071,064,600
$47.13+1.22+2.7%$46.02$48.03$45.58815,700
$45.91-1.46-3.1%$47.08$47.38$45.101,394,300
$47.37-1.85-3.8%$48.93$49.20$46.96601,700
$49.22-0.13-0.3%$49.61$49.81$48.50318,900
$49.35-0.57-1.1%$49.75$50.07$48.45937,200
$49.92+0.91+1.9%$49.65$51.02$49.37463,890
$49.01-0.08-0.2%$48.61$49.33$47.62822,246
$49.09-1.43-2.8%$50.70$51.11$49.01592,500
$50.52-3.61-6.7%$54.15$54.60$50.331,429,100
Ticker
NASDAQ:GPCR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Structure Therapeutics, Inc. news

Structure Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in the last 12 months · 2 in all · newest Nov 4, 2026 · oldest 2026
Decks
7 decks · latest Sep 8, 2026

Valuation

Price/book 0.9× against a median of 4.2×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$82.92M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.38

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Structure Therapeutics, Inc. · NASDAQ:GPCRUS$1.15B−US$82.92Mn/an/an/a0.9×n/a0.0×1.38
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Vor Biopharma Inc. · NASDAQ:VORUS$1.18BUS$697.4M0.9×n/an/an/an/an/a1.25
Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204US$1.17BUS$1.01Bn/a36.1×n/a3.9×−53.3%0.0×n/a
OPKO Health, Inc. · NASDAQ:OPKUS$1.17BUS$1.26Bn/a2.5×n/a1.0×−29.5%0.4×0.90
D&D Pharmatech Co., Ltd. · KRX:347850US$1.16BUS$1.13Bn/a549×n/a11.5×−785.5%0.8×n/a
CStone Pharmaceuticals · HKEX:2616US$1.16BUS$974.9Mn/a24.1×n/a6.0×−162.1%0.3×n/a
COMPASS Pathways Plc · NASDAQ:CMPSUS$1.14BUS$747.8Mn/an/an/a8.0×n/a0.4×1.65
Ascentage Pharma Group International · HKEX:6855US$1.11BUS$1.14Bn/a13.7×n/a13.4×−216.5%3.8×n/a
Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321US$1.10BUS$1.10B102×6.8×n/a2.9×6.6%0.5×n/a
Pharma Mar SA · BME:PHMUS$1.10BUS$978.5M14.6×3.8×16.6×4.2×28.8%0.3×n/a
Median of the othersUS$1.16BUS$993.9M14.6×13.7×16.6×4.2×−53.3%0.4×1.27

Forecasts

11 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
104.31 USD · Analysts' mean
EPS, year to Dec 2026
-2.20 · 4 analysts

Team and board

OfficerRole
Jun YoonChief Financial Officer

Events

Next results
Feb 25, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close+1.5%
Q2 2026Aug 6, 2026 · After close+1.0%
Q1 2026May 7, 2026 · After close−0.1%
Q4 2025Feb 26, 2026−5.3%
Q3 2025Nov 6, 2025 · After close−1.9%
Q2 2025Aug 6, 2025 · After close−0.7%
Q1 2025May 8, 2025 · After close−4.7%
Q4 2024Feb 27, 2025+19.5%
Q3 2024Nov 13, 2024 · After close+3.6%
Q2 2024Aug 8, 2024 · After close−2.1%
All 16 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−7.3%
Q4 2023Mar 8, 2024 · Before open+2.4%
Q3 2023Nov 14, 2023 · After close−9.8%
Q2 2023Aug 10, 2023 · After close−6.1%
Q1 2023May 11, 2023 · After close+5.6%
Q4 2022Mar 31, 2023 · After close+9.9%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (September 2026)Corporate update35 slidesSep 8, 2026
Investor Presentation (June 2026)Investor deck21 slidesJune 2026
Corporate Update (March 2026)Corporate update35 slidesMar 16, 2026
Technical Presentation (December 2025)Technical47 slidesDec 8, 2025
Corporate Update (June 2024)Corporate update31 slidesJun 3, 2024
Corporate Update (December 2023)Corporate update35 slidesDec 18, 2023
Corporate Update (September 2023)Corporate update24 slidesSep 29, 2023

Open Decks

IPO

Priced at US$15.00 an ADS on Feb 2, 2023.

Price
US$15.00 an ADS
ADSs offered
10,740,000 American depositary shares
Offering size
US$161.1 million
Underwriters' option
Up to 1,611,000 more ADSs
Listing
GPCR on the Nasdaq Global Market
Underwriters
Jefferies, SVB Securities, Guggenheim Securities, BMO Capital Markets · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 14, 2022
Filed publiclyJan 12, 2023
Amended onceJan 30, 2023
Shares registered with an exchangeJan 30, 2023
Declared effective by the SECFeb 2, 2023
Final prospectus, with the priceFeb 6, 2023

Open IPO · From the cover of the final prospectus (424B4) filed Feb 6, 2023

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue3.90M2.60M949.2K623.3K266.4K20.0K
Gross profit-3.90M-2.60M-949.2K-623.3K-266.4K-20.0K
Research and development225.3M108.8M70.1M36.2M29.1M12.4K
Selling, general and administrative61.6M49.4M32.7M16.4M8.59M3.54K
Operating income-176.6M-158.2M-102.8M-52.6M-37.7M-15.9K
Depreciation and amortization1.33M992.0K295.0K277.0K72.0K20.0K
EBITDA-175.2M-157.2M-102.5M-52.3M-37.6M4.13K
Interest expense13.4M1.53M122.2K5
Income before tax-140.7M-122.2M-89.4M-51.3M-37.8M-15.7K
Income tax515.0K310.0K236.0K17.0K231.0K138
Net income-141.2M-122.5M-89.6M-51.3M-40.0M-15.9K
Earnings per share, basic-0.80-0.78-0.81-5.51-1.09-0.00
Earnings per share, diluted-0.80-0.78-0.81-5.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents799.6M169.5M129.8M26.1M105.3M16.4M
Short-term investments646.6M714.0M337.5M64.8M2.00M21.1M
Current assets1.57B891.2M473.6M93.1M109.3M38.4M
Property, plant and equipment6.65M3.48M3.23M1.03M1.79M277.0K
Total assets1.58B903.3M482.0M97.8M111.2M38.7M
Accounts payable13.9M8.02M4.74M6.01M3.48M1.53M
Current liabilities63.3M36.0M24.7M13.0M8.66M3.04M
Total debt6.49M3.86M5.45M260.0K621.0K280.0K
Total liabilities67.5M38.5M29.1M13.0M175.9M61.2M
Shareholders' equity1.52B864.8M453.0M-115.1M-64.7M-22.5M
Shares outstanding212.5M171.9M139.2M10.5M36.6M36.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-222.2M-116.6M-79.5M-46.1M-32.2M-14.3M
Capital spending-3.61M-1.29M-2.17M-155.0K-1.21M-19.0K
Free cash flow-225.8M-117.9M-81.7M-46.3M-33.4M-14.3M
Cash from investing89.8M-358.9M-268.3M-62.1M17.9M-21.1M
Cash from financing762.5M515.3M451.5M29.0M103.3M25.8M
Share buybacks-6.00K
Change in cash630.1M39.7M103.7M-79.2M89.0M-9.59M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 7, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2026Insider tradeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipJul 24, 2026Insider tradeSEC
4 · Change in ownershipJul 15, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
424B5 · ProspectusMay 7, 2026Offer documentSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportApr 15, 2026Management or board changeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
8-K · Current reportMar 16, 2026Current reportSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026Material contractSEC
8-K · Current reportDec 10, 2025Current reportSEC
424B5 · ProspectusDec 10, 2025Offer documentSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
424B5 · ProspectusDec 8, 2025Offer documentSEC
8-K · Current reportDec 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 18, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
S-3ASR · Registration statementAug 6, 2025Offer documentSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 13, 2025Big-stake noticeSEC
8-K · Current reportDec 17, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 20, 2024Insider tradeSEC
8-K · Current reportSep 17, 2024Management or board changeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 28, 2024Insider tradeSEC
8-K · Current reportAug 27, 2024Management or board changeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJun 27, 2024Meeting outcomeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
144 · Notice of proposed saleJun 10, 2024Other filingsSEC
424B4 · ProspectusJun 6, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 6, 2024Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJun 5, 2024Offer documentSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
UPLOAD · Letter from the SECJun 4, 2024Other filingsSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
8-K · Current reportJun 3, 2024Current reportSEC
144 · Notice of proposed saleJun 3, 2024Other filingsSEC
S-1 · Registration statementJun 3, 2024Offer documentSEC
8-K · Current reportJun 3, 2024Current reportSEC
CORRESP · Letter to the SECMay 31, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 31, 2024Other filingsSEC
SC 13G · Big-stake noticeMay 30, 2024Big-stake noticeSEC
CORRESP · Letter to the SECMay 24, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 22, 2024Other filingsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
4 · Change in ownershipApr 19, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 20, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 20, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 20, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 20, 2024Insider tradeSEC
4/A · Change in ownership, amendedMar 20, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 8, 2024Offer documentSEC
10-K · Annual reportMar 8, 2024Annual reportSEC
8-K · Current reportMar 8, 2024ResultsSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
4 · Change in ownershipDec 27, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedDec 20, 2023Big-stake noticeSEC
8-K · Current reportDec 18, 2023Current reportSEC
4 · Change in ownershipDec 7, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveNov 30, 2023Other filingsSEC
CORRESP · Letter to the SECNov 27, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 24, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 24, 2023Other filingsSEC
DRS · Draft registration statementNov 20, 2023Offer documentSEC
S-1 · Registration statementNov 17, 2023Offer documentSEC
10-Q · Quarterly reportNov 17, 2023Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 17, 2023Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 16, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2023Explanation requestSEC
8-K · Current reportNov 14, 2023ResultsSEC

This page holds 200 of 275 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Structure Therapeutics, Inc.’s releases

Common shares
71,309,857
Fully diluted
71,309,857

Fully diluted

LineShares
Common shares71,309,857

Share count over time

CountShares
Nov 22, 202671,309,857

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Wellington9.76M4.5%US$305MSep 30, 2026
Fidelity9.35M4.4%US$293MSep 30, 2026
Avoro Capital Advisors LLC6.56M3.1%US$205MSep 30, 2026
Janus Henderson5.07M2.4%US$159MSep 30, 2026
Deep Track Capital, LP5M2.3%US$156MSep 30, 2026
Morgan Stanley2.82M1.3%US$88.1MSep 30, 2026
Bvf Inc2.69M1.3%US$84.2MSep 30, 2026
Rtw Investments, LP2.28M1.1%US$71.4MSep 30, 2026
Baker Bros. Advisors LP1.43M0.67%US$44.8MSep 30, 2026
Orbimed Advisors LLC1.33M0.62%US$41.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Paradigm Biocapital Advisors LP1.3M0.60%US$40.6MSep 30, 2026
Principal1.26M0.59%US$39.6MSep 30, 2026
Deerfield Management Company, L.P.1.09M0.51%US$34MSep 30, 2026
Casdin Capital, LLC1.03M0.48%US$32.2MSep 30, 2026
Logos Global Management LP1M0.47%US$31.3MSep 30, 2026
Siren, L.L.C.873K0.41%US$27.3MSep 30, 2026
abrdn859K0.40%US$26.9MSep 30, 2026
Capitolis Liquid Global Markets LLC835K0.39%US$26.1MSep 30, 2026
Driehaus Capital Management LLC804K0.37%US$25.1MSep 30, 2026
Pacific Heights Asset Management LLC800K0.37%US$25MSep 30, 2026
BlackRock706K0.33%US$22.1MSep 30, 2026
Rock Springs Capital Management LP640K0.30%US$20MSep 30, 2026
AllianceBernstein582K0.27%US$18.2MSep 30, 2026
JPMorgan546K0.25%US$17.9MSep 30, 2026
Blue Sparrow, LLC473K0.22%US$14.8MSep 30, 2026
Two Sigma442K0.21%US$13.8MSep 30, 2026
Goldman Sachs431K0.20%US$13.5MSep 30, 2026
T. Rowe Price378K0.18%US$11.8MSep 30, 2026
Franklin Templeton371K0.17%US$7.56MSep 30, 2026
UBS332K0.15%US$10.4MSep 30, 2026
National Bank Of Canada319K0.15%US$9.96MSep 30, 2026
NEXTBio Capital Management LP312K0.15%US$9.77MSep 30, 2026
American Century304K0.14%US$9.5MSep 30, 2026
Parkman Healthcare Partners LLC284K0.13%US$8.87MSep 30, 2026
HSG Holding Ltd266K0.12%US$8.32MSep 30, 2026
Catalio Capital Management, LP260K0.12%US$8.13MSep 30, 2026
Susquehanna250K0.12%US$7.83MSep 30, 2026
SEB Asset Management AB245K0.11%US$7.66MSep 30, 2026
Jane Street233K0.11%US$7.28MSep 30, 2026
Trexquant Investment LP200K0.09%US$6.26MSep 30, 2026
Rhenman & Partners Asset Management AB183K0.09%US$5.73MSep 30, 2026
B Group, Inc.180K0.08%US$5.63MSep 30, 2026
HighVista Strategies LLC170K0.08%US$5.32MSep 30, 2026
Eversept Partners, LP155K0.07%US$4.85MSep 30, 2026
Woodline Partners LP154K0.07%US$4.81MSep 30, 2026
Bank of America150K0.07%US$4.69MSep 30, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH141K0.07%US$4.4MSep 30, 2026
Healthcare Of Ontario Pension Plan Trust Fund135K0.06%US$4.23MSep 30, 2026
Nomura124K0.06%US$3.87MSep 30, 2026
Jefferies Financial Group Inc.122K0.06%US$1.28MSep 30, 2026

This page holds 50 of 165 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
FMR LLC15.00%32.1MSep 30, 2026Schedule 13G
Wellington Management Group LLP13.60%29.3MSep 30, 2026Schedule 13G
Deep Track Capital, LP7.18%15MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Eric Dobmeier
Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Janux Therapeutics, Inc. (Director · Since at least Jul 19, 2024); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 14, 2021 · Past)
Director · Since at least Feb 2, 2023
Matthew Lang
Other companies: Metsera, Inc. (CHIEF LEGAL OFFICER · Since at least Apr 28, 2025); Lyell Immunopharma, Inc. (Chief Business Officer · Jul 1, 2023 – Feb 10, 2025 · Past); Myovant Sciences Ltd (General Counsel & Corp. Secy. · Apr 5, 2019 – Mar 10, 2023 · Past)
COO & GC · Since at least Apr 15, 2026
Ashley Hall
Other companies: OnKure Therapeutics, Inc. (Chief Development Officer · Oct 11, 2020 – Aug 28, 2023 · Past); Esperion Therapeutics, Inc. (Chief Development Officer · Feb 26, 2020 – Jan 28, 2021 · Past)
Chief Development Officer · Since at least Sep 18, 2024
Joanne Waldstreicher
Other companies: Becton, Dickinson and Company (Director · Since at least Jul 24, 2023)
Director · Since at least Feb 2, 2023
John Joseph BerriosChief Commercial Officer · Since at least Aug 6, 2026
Jun YoonChief Financial Officer · Since at least Nov 5, 2026
Xichen LinCHIEF SCIENTIFIC OFFICER · Since at least Feb 2, 2023

Open People

Log in to ask 6ix AI your own questions about Structure Therapeutics, Inc.